Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial (2024)

Abstract

Background: S-isomer (S) pantoprazole is known to be more effective and less dependent on cytochrome 2C19 than R-isomer (R)-pantoprazole. Aim: The purpose of this study was to compare the efficacy and safety of S-pantoprazole 20 mg versus pantoprazole 40 mg for treatment of reflux esophagitis. Methods: This multi-center, double-blind, randomized trial enrolled patients with endoscopically documented reflux esophagitis. Patients were assigned to receive either 20 mg S-pantoprazole or 40 mg pantoprazole once daily for 4 weeks. Endoscopy and symptoms were assessed after 4 weeks of treatment. In patients whose reflux esophagitis was not resolved at 4 weeks, treatment was extended to 8 weeks and symptoms were reassessed. Heartburn, chest pain, acid regurgitation, globus, and overall symptoms were rated. The primary efficacy endpoint was healing of esophagitis, and secondary endpoints were symptomatic and endoscopic improvement. Results: Sixty-seven patients in the S-pantoprazole group (52 male, mean age 51 years) and 62 in the pantoprazole group (61 male, mean age 50 years) were analyzed per protocol. The healing rate of reflux esophagitis was 85 % at 4 weeks and 94 % at 8 weeks in the S-pantoprazole group, which did not differ from those in the pantoprazole group (84 and 97 %, respectively). After treatment, individual and overall gastroesophageal reflux disease (GERD) symptoms and esophagitis improved compared with baseline inflammation in both groups. Intergroup differences in symptoms and endoscopic healing were not significant. Conclusion: The efficacy and safety of 20 mg S-pantoprazole were comparable to those of 40 mg pantoprazole for treatment of reflux esophagitis and symptomatic improvement of GERD.

Original languageEnglish
Pages (from-to)3189-3194
Number of pages6
JournalDigestive Diseases and Sciences
Volume57
Issue number12
DOIs
Publication statusPublished - 2012 Dec 1

Keywords

  • Efficacy
  • Enantiomer
  • Pantoprazole
  • Proton pump inhibitor
  • Racemate

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Fingerprint

Dive into the research topics of 'Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial'. Together they form a unique fingerprint.

Cite this

  • APA
  • Standard
  • Harvard
  • Vancouver
  • Author
  • BIBTEX
  • RIS

Cho, Y. K., Choi, M. G., Bak, Y.-T., Rhee, P. L., Kim, S. G., Jung, H. Y., & Seol, S. Y. (2012). Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial. Digestive Diseases and Sciences, 57(12), 3189-3194. https://doi.org/10.1007/s10620-012-2297-y

Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial. / Cho, Yu Kyung; Choi, Myung Gyu; Bak, Young-Tae et al.
In: Digestive Diseases and Sciences, Vol. 57, No. 12, 01.12.2012, p. 3189-3194.

Research output: Contribution to journalArticlepeer-review

Cho, YK, Choi, MG, Bak, Y-T, Rhee, PL, Kim, SG, Jung, HY & Seol, SY 2012, 'Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial', Digestive Diseases and Sciences, vol. 57, no. 12, pp. 3189-3194. https://doi.org/10.1007/s10620-012-2297-y

Cho YK, Choi MG, Bak YT, Rhee PL, Kim SG, Jung HY et al. Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial. Digestive Diseases and Sciences. 2012 Dec 1;57(12):3189-3194. doi: 10.1007/s10620-012-2297-y

Cho, Yu Kyung ; Choi, Myung Gyu ; Bak, Young-Tae et al. / Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis : A randomized, double-blind comparative trial. In: Digestive Diseases and Sciences. 2012 ; Vol. 57, No. 12. pp. 3189-3194.

@article{d1b5e37a5c004270982e7e341478239d,

title = "Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial",

abstract = "Background: S-isomer (S) pantoprazole is known to be more effective and less dependent on cytochrome 2C19 than R-isomer (R)-pantoprazole. Aim: The purpose of this study was to compare the efficacy and safety of S-pantoprazole 20 mg versus pantoprazole 40 mg for treatment of reflux esophagitis. Methods: This multi-center, double-blind, randomized trial enrolled patients with endoscopically documented reflux esophagitis. Patients were assigned to receive either 20 mg S-pantoprazole or 40 mg pantoprazole once daily for 4 weeks. Endoscopy and symptoms were assessed after 4 weeks of treatment. In patients whose reflux esophagitis was not resolved at 4 weeks, treatment was extended to 8 weeks and symptoms were reassessed. Heartburn, chest pain, acid regurgitation, globus, and overall symptoms were rated. The primary efficacy endpoint was healing of esophagitis, and secondary endpoints were symptomatic and endoscopic improvement. Results: Sixty-seven patients in the S-pantoprazole group (52 male, mean age 51 years) and 62 in the pantoprazole group (61 male, mean age 50 years) were analyzed per protocol. The healing rate of reflux esophagitis was 85 % at 4 weeks and 94 % at 8 weeks in the S-pantoprazole group, which did not differ from those in the pantoprazole group (84 and 97 %, respectively). After treatment, individual and overall gastroesophageal reflux disease (GERD) symptoms and esophagitis improved compared with baseline inflammation in both groups. Intergroup differences in symptoms and endoscopic healing were not significant. Conclusion: The efficacy and safety of 20 mg S-pantoprazole were comparable to those of 40 mg pantoprazole for treatment of reflux esophagitis and symptomatic improvement of GERD.",

keywords = "Efficacy, Enantiomer, Pantoprazole, Proton pump inhibitor, Racemate",

author = "Cho, {Yu Kyung} and Choi, {Myung Gyu} and Young-Tae Bak and Rhee, {Poong Lyul} and Kim, {Sang Gyun} and Jung, {Hoon Yong} and Seol, {Sang Young}",

year = "2012",

month = dec,

day = "1",

doi = "10.1007/s10620-012-2297-y",

language = "English",

volume = "57",

pages = "3189--3194",

journal = "Digestive Diseases and Sciences",

issn = "0163-2116",

publisher = "Springer New York",

number = "12",

}

TY - JOUR

T1 - Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis

T2 - A randomized, double-blind comparative trial

AU - Cho, Yu Kyung

AU - Choi, Myung Gyu

AU - Bak, Young-Tae

AU - Rhee, Poong Lyul

AU - Kim, Sang Gyun

AU - Jung, Hoon Yong

AU - Seol, Sang Young

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background: S-isomer (S) pantoprazole is known to be more effective and less dependent on cytochrome 2C19 than R-isomer (R)-pantoprazole. Aim: The purpose of this study was to compare the efficacy and safety of S-pantoprazole 20 mg versus pantoprazole 40 mg for treatment of reflux esophagitis. Methods: This multi-center, double-blind, randomized trial enrolled patients with endoscopically documented reflux esophagitis. Patients were assigned to receive either 20 mg S-pantoprazole or 40 mg pantoprazole once daily for 4 weeks. Endoscopy and symptoms were assessed after 4 weeks of treatment. In patients whose reflux esophagitis was not resolved at 4 weeks, treatment was extended to 8 weeks and symptoms were reassessed. Heartburn, chest pain, acid regurgitation, globus, and overall symptoms were rated. The primary efficacy endpoint was healing of esophagitis, and secondary endpoints were symptomatic and endoscopic improvement. Results: Sixty-seven patients in the S-pantoprazole group (52 male, mean age 51 years) and 62 in the pantoprazole group (61 male, mean age 50 years) were analyzed per protocol. The healing rate of reflux esophagitis was 85 % at 4 weeks and 94 % at 8 weeks in the S-pantoprazole group, which did not differ from those in the pantoprazole group (84 and 97 %, respectively). After treatment, individual and overall gastroesophageal reflux disease (GERD) symptoms and esophagitis improved compared with baseline inflammation in both groups. Intergroup differences in symptoms and endoscopic healing were not significant. Conclusion: The efficacy and safety of 20 mg S-pantoprazole were comparable to those of 40 mg pantoprazole for treatment of reflux esophagitis and symptomatic improvement of GERD.

AB - Background: S-isomer (S) pantoprazole is known to be more effective and less dependent on cytochrome 2C19 than R-isomer (R)-pantoprazole. Aim: The purpose of this study was to compare the efficacy and safety of S-pantoprazole 20 mg versus pantoprazole 40 mg for treatment of reflux esophagitis. Methods: This multi-center, double-blind, randomized trial enrolled patients with endoscopically documented reflux esophagitis. Patients were assigned to receive either 20 mg S-pantoprazole or 40 mg pantoprazole once daily for 4 weeks. Endoscopy and symptoms were assessed after 4 weeks of treatment. In patients whose reflux esophagitis was not resolved at 4 weeks, treatment was extended to 8 weeks and symptoms were reassessed. Heartburn, chest pain, acid regurgitation, globus, and overall symptoms were rated. The primary efficacy endpoint was healing of esophagitis, and secondary endpoints were symptomatic and endoscopic improvement. Results: Sixty-seven patients in the S-pantoprazole group (52 male, mean age 51 years) and 62 in the pantoprazole group (61 male, mean age 50 years) were analyzed per protocol. The healing rate of reflux esophagitis was 85 % at 4 weeks and 94 % at 8 weeks in the S-pantoprazole group, which did not differ from those in the pantoprazole group (84 and 97 %, respectively). After treatment, individual and overall gastroesophageal reflux disease (GERD) symptoms and esophagitis improved compared with baseline inflammation in both groups. Intergroup differences in symptoms and endoscopic healing were not significant. Conclusion: The efficacy and safety of 20 mg S-pantoprazole were comparable to those of 40 mg pantoprazole for treatment of reflux esophagitis and symptomatic improvement of GERD.

KW - Efficacy

KW - Enantiomer

KW - Pantoprazole

KW - Proton pump inhibitor

KW - Racemate

UR - http://www.scopus.com/inward/record.url?scp=84871638481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871638481&partnerID=8YFLogxK

U2 - 10.1007/s10620-012-2297-y

DO - 10.1007/s10620-012-2297-y

M3 - Article

C2 - 22772870

AN - SCOPUS:84871638481

SN - 0163-2116

VL - 57

SP - 3189

EP - 3194

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

IS - 12

ER -

Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial (2024)
Top Articles
Latest Posts
Article information

Author: Tyson Zemlak

Last Updated:

Views: 6586

Rating: 4.2 / 5 (63 voted)

Reviews: 94% of readers found this page helpful

Author information

Name: Tyson Zemlak

Birthday: 1992-03-17

Address: Apt. 662 96191 Quigley Dam, Kubview, MA 42013

Phone: +441678032891

Job: Community-Services Orchestrator

Hobby: Coffee roasting, Calligraphy, Metalworking, Fashion, Vehicle restoration, Shopping, Photography

Introduction: My name is Tyson Zemlak, I am a excited, light, sparkling, super, open, fair, magnificent person who loves writing and wants to share my knowledge and understanding with you.